Guangming Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Guangming Li has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Jixiang Wu
Department of General Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China
11 shared publications Chaojie Liang
Department of General Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
10 shared publicationsHua Ge
Department of General Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
9 shared publicationsYingchen Xu
Department of General Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
8 shared publicationsGuanqun Li
Department of General Surgery, Beijing Tongren Hospital, Capital Medical University, Dongcheng, Beijing 100730, China
2 shared publicationsBing Zhang
Department of Tumor Center, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
1 shared publication
Latest Publications
- 1 November 2018
- Published by Elsevier in Clinica Chimica Acta
- Vol. 486, 357-368
Long non-coding RNA CASC2 in solid tumors: A meta-analysis
- 1 November 2018
- Published by Elsevier in Clinica Chimica Acta
- Vol. 486, 357-368
Long non-coding RNA CASC2 in solid tumors: A meta-analysis
- 1 September 2018
- Published by Elsevier in Clinica Chimica Acta
- Vol. 484, 91-98
The clinicopathological and prognostic value of long non-coding RNA ZEB1-AS1 in solid tumors: A meta-analysis
- 1 September 2018
- Published by Elsevier in Clinica Chimica Acta
- Vol. 484, 91-98
The clinicopathological and prognostic value of long non-coding RNA ZEB1-AS1 in solid tumors: A meta-analysis
- Open Access
- 1 June 2018
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 3561-3571
Clinicopathological and prognostic significance of FoxM1 in hepatocellular carcinoma patients: a meta-analysis
Background and aims: Recently, the abnormal expression of FoxM1 has been found in many malignant tumors. However, the clinicopathological and prognostic value of FoxM1 expression in hepatocellular carcinoma (HCC) patients remains controversial. We conducted a meta-analysis to establish the relationship between FoxM1 expression and the clinicopathological features and prognostic value in patients with HCC. Methods: An electronic search for relevant articles was conducted according to a set of criteria in the PubMed, Cochrane Library, Web of Science, EMBASE, Chinese CNKI and Chinese WanFang databases. The correlation data between FoxM1 expression and clinicopathological features and survival outcomes were analyzed. Pooled odds ratios (ORs) and hazard ratios (HRs) with 95% CIs were calculated using STATA14.2. Results: A total of 14 studies comprising of 2,036 patients were enrolled in this meta-analysis. The results showed that FoxM1 expression was related to the incidence, tumor size (>5 cm), vascular invasion, differentiation and TNM stage. Moreover, overexpression of FoxM1 indicated a poor 3- and 5-year overall survival rate (OS) and recurrence-free survival rate (disease-free survival rate). Conclusion: Our meta-analysis indicated that FoxM1 expression was associated with incidence, tumor size (>5 cm), vascular invasion, differentiation and TNM stage. Accordingly, FoxM1 may be a reliable prognostic biomarker for patients with HCC. However, additional high-quality studies are still needed to further support these findings.
- 1 June 2018
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 3561-3571
Open AccessClinicopathological and prognostic significance of FoxM1 in hepatocellular carcinoma patients: a meta-analysis
Background and aims: Recently, the abnormal expression of FoxM1 has been found in many malignant tumors. However, the clinicopathological and prognostic value of FoxM1 expression in hepatocellular carcinoma (HCC) patients remains controversial. We conducted a meta-analysis to establish the relationship between FoxM1 expression and the clinicopathological features and prognostic value in patients with HCC. Methods: An electronic search for relevant articles was conducted according to a set of criteria in the PubMed, Cochrane Library, Web of Science, EMBASE, Chinese CNKI and Chinese WanFang databases. The correlation data between FoxM1 expression and clinicopathological features and survival outcomes were analyzed. Pooled odds ratios (ORs) and hazard ratios (HRs) with 95% CIs were calculated using STATA14.2. Results: A total of 14 studies comprising of 2,036 patients were enrolled in this meta-analysis. The results showed that FoxM1 expression was related to the incidence, tumor size (>5 cm), vascular invasion, differentiation and TNM stage. Moreover, overexpression of FoxM1 indicated a poor 3- and 5-year overall survival rate (OS) and recurrence-free survival rate (disease-free survival rate). Conclusion: Our meta-analysis indicated that FoxM1 expression was associated with incidence, tumor size (>5 cm), vascular invasion, differentiation and TNM stage. Accordingly, FoxM1 may be a reliable prognostic biomarker for patients with HCC. However, additional high-quality studies are still needed to further support these findings.
- 1 June 2018
- Published by Elsevier in Clinica Chimica Acta
- Vol. 481, 99-107
Long non-coding RNA CRNDE as a potential prognostic biomarker in solid tumors: A meta-analysis
- 1 June 2018
- Published by Elsevier in Clinica Chimica Acta
- Vol. 481, 99-107
Long non-coding RNA CRNDE as a potential prognostic biomarker in solid tumors: A meta-analysis
- Open Access
- 1 April 2018
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 2387-2397
Role of Beclin1 expression in patients with hepatocellular carcinoma: a meta-analysis
Dove Press is a member of the Open Access Initiative, specializing in peer reviewed Medical Journals. View articles or submit your research for publishing.
- 1 April 2018
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 2387-2397
Open AccessRole of Beclin1 expression in patients with hepatocellular carcinoma: a meta-analysis
Dove Press is a member of the Open Access Initiative, specializing in peer reviewed Medical Journals. View articles or submit your research for publishing.
- 28 March 2018
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 53, 193-200
The clinicopathological and prognostic value of Nanog in human gastrointestinal luminal cancer: A meta-analysis
Background: Recent studies have demonstrated that the over-expression of Nanog contributes to the progression of various malignant tumors. However, the clinicopathological and prognostic role of Nanog in gastrointestinal luminal cancer remains controversial. Therefore, we conducted a meta-analysis to assess the role of Nanog in gastrointestinal luminal cancer. Methods: An electronic search for relevant literature was performed in PubMed, Cochrane Library, Web of Science, and EMBASE databases. The relationships between Nanog expression and clinicopathological features and survival outcomes were analyzed. Pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated by STATA14.2 and RevMan 5.3 software. Results: A total of 9 studies with 1526 patients were included in this meta-analysis. The positive expression of Nanog was related to gender, depth of infiltration, differentiation, and TNM stage; however, it was not associated with age, tumor size, or lymph node metastasis. Moreover, positive Nanog expression was correlated with a poor overall survival (OS) and poor disease-free survival (DFS) in gastrointestinal luminal cancer. Conclusion: The pooled results suggested that Nanog expression was associated with gender, depth of infiltration, differentiation, and TNM stage, and Nanog may be a potential biomarker to predict the prognosis of gastrointestinal luminal cancer.
- 28 March 2018
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 53, 193-200
The clinicopathological and prognostic value of Nanog in human gastrointestinal luminal cancer: A meta-analysis
Background: Recent studies have demonstrated that the over-expression of Nanog contributes to the progression of various malignant tumors. However, the clinicopathological and prognostic role of Nanog in gastrointestinal luminal cancer remains controversial. Therefore, we conducted a meta-analysis to assess the role of Nanog in gastrointestinal luminal cancer. Methods: An electronic search for relevant literature was performed in PubMed, Cochrane Library, Web of Science, and EMBASE databases. The relationships between Nanog expression and clinicopathological features and survival outcomes were analyzed. Pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated by STATA14.2 and RevMan 5.3 software. Results: A total of 9 studies with 1526 patients were included in this meta-analysis. The positive expression of Nanog was related to gender, depth of infiltration, differentiation, and TNM stage; however, it was not associated with age, tumor size, or lymph node metastasis. Moreover, positive Nanog expression was correlated with a poor overall survival (OS) and poor disease-free survival (DFS) in gastrointestinal luminal cancer. Conclusion: The pooled results suggested that Nanog expression was associated with gender, depth of infiltration, differentiation, and TNM stage, and Nanog may be a potential biomarker to predict the prognosis of gastrointestinal luminal cancer.
- Open Access
- 1 March 2018
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 1293-1303
The clinicopathological and prognostic value of HSP27 in hepatocellular carcinoma: a systematic review and meta-analysis
Background: In the recent past, there is increasing evidence demonstrating that HSP27 plays a key role in tumor progression. However, the relationship between HSP27 expression and the clinicopathological features of hepatocellular carcinoma (HCC), as well as its prognostic value in HCC patients remain controversial. Accordingly, we conducted a meta-analysis to assess the correlation between HSP27 expression and HCC, and determine the prognostic value of HSP27 in HCC. Methods: The data included clinicopathological features and survival information extracted from the published literature in the databases PubMed, EMBASE, Cochrane Library, Web of Science, CNKI, and Wan Fang. The pooled odds ratios and hazard ratios with 95% CIs were calculated using Forest plot analysis. Results: The meta-analysis results indicated that the positive HSP27 expression was significantly correlated with HCC incidence, tumor differentiation, and α-fetoprotein level in patients with HCC. However, the expression of HSP27 was not associated with metastasis, hepatitis B virus surface antigen, gender, tumor size, TNM stage, and vascular invasion. Additionally, HSP27 expression indicated a poor overall survival rate, but it was not related to disease-free survival rate. Conclusion: This meta-analysis revealed that HSP27 may play a key role in the development of HCC and could be a reliable biomarker for the prognosis of patients with HCC. However, additional high-quality research is needed to support the results.
- 1 March 2018
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 1293-1303
Open AccessThe clinicopathological and prognostic value of HSP27 in hepatocellular carcinoma: a systematic review and meta-analysis
Background: In the recent past, there is increasing evidence demonstrating that HSP27 plays a key role in tumor progression. However, the relationship between HSP27 expression and the clinicopathological features of hepatocellular carcinoma (HCC), as well as its prognostic value in HCC patients remain controversial. Accordingly, we conducted a meta-analysis to assess the correlation between HSP27 expression and HCC, and determine the prognostic value of HSP27 in HCC. Methods: The data included clinicopathological features and survival information extracted from the published literature in the databases PubMed, EMBASE, Cochrane Library, Web of Science, CNKI, and Wan Fang. The pooled odds ratios and hazard ratios with 95% CIs were calculated using Forest plot analysis. Results: The meta-analysis results indicated that the positive HSP27 expression was significantly correlated with HCC incidence, tumor differentiation, and α-fetoprotein level in patients with HCC. However, the expression of HSP27 was not associated with metastasis, hepatitis B virus surface antigen, gender, tumor size, TNM stage, and vascular invasion. Additionally, HSP27 expression indicated a poor overall survival rate, but it was not related to disease-free survival rate. Conclusion: This meta-analysis revealed that HSP27 may play a key role in the development of HCC and could be a reliable biomarker for the prognosis of patients with HCC. However, additional high-quality research is needed to support the results.
- Open Access
- 1 March 2018
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 1203-1214
Clinicopathological significance and prognostic role of p-STAT3 in patients with hepatocellular carcinoma
Background and aim: Constitutive activation of STAT3 through its phosphorylation (p-STAT3) plays a key role in the development and progression of various cancers. However, the relationship between p-STAT3 expression and the clinicopathological features and prognostic value in patients with hepatocellular carcinoma (HCC) remains controversial. We conducted a meta-analysis to evaluate the role of p-STAT3 in HCC. Methods: The PubMed, Cochrane Library, Web of Science, EMBASE, Chinese CNKI, and Chinese Wanfang databases were searched using the appropriate terms to find the relevant studies on p-STAT3 and HCC. The relationship between p-STAT3 expression and clinicopathological characteristics and prognostic value was established. Pool odds ratios (ORs) and hazard ratios (HRs) with 95% CIs were calculated using the STATA 14.2 software. Results: The eight articles included in this meta-analysis comprised 752 patients. Expression of p-STAT3 was associated with incidence, age, liver cirrhosis, tumor size, vascular invasion, and TNM stage of HCC, but it was not related to gender, alpha-fetoprotein (AFP), hepatitis B surface antigen (HBsAg), number of tumors, and tumor differentiation. Additionally, the expression of p-STAT3 was related to a poor 3- and 5-year overall survival rate and disease-free survival rate. Conclusion: Expression of p-STAT3 was associated with the incidence, age, liver cirrhosis, tumor size, vascular invasion, and TNM stage. Thus, p-STAT3 can be a reliable prognostic biomarker for HCC. Further high-quality studies with larger numbers of patients are needed.
- 1 March 2018
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 1203-1214
Open AccessClinicopathological significance and prognostic role of p-STAT3 in patients with hepatocellular carcinoma
Background and aim: Constitutive activation of STAT3 through its phosphorylation (p-STAT3) plays a key role in the development and progression of various cancers. However, the relationship between p-STAT3 expression and the clinicopathological features and prognostic value in patients with hepatocellular carcinoma (HCC) remains controversial. We conducted a meta-analysis to evaluate the role of p-STAT3 in HCC. Methods: The PubMed, Cochrane Library, Web of Science, EMBASE, Chinese CNKI, and Chinese Wanfang databases were searched using the appropriate terms to find the relevant studies on p-STAT3 and HCC. The relationship between p-STAT3 expression and clinicopathological characteristics and prognostic value was established. Pool odds ratios (ORs) and hazard ratios (HRs) with 95% CIs were calculated using the STATA 14.2 software. Results: The eight articles included in this meta-analysis comprised 752 patients. Expression of p-STAT3 was associated with incidence, age, liver cirrhosis, tumor size, vascular invasion, and TNM stage of HCC, but it was not related to gender, alpha-fetoprotein (AFP), hepatitis B surface antigen (HBsAg), number of tumors, and tumor differentiation. Additionally, the expression of p-STAT3 was related to a poor 3- and 5-year overall survival rate and disease-free survival rate. Conclusion: Expression of p-STAT3 was associated with the incidence, age, liver cirrhosis, tumor size, vascular invasion, and TNM stage. Thus, p-STAT3 can be a reliable prognostic biomarker for HCC. Further high-quality studies with larger numbers of patients are needed.
- Open Access
- 1 December 2017
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 47-57
Clinicopathological and prognostic significance of OCT4 in patients with hepatocellular carcinoma: a meta-analysis
Background and aims: Octamer-binding transcription factor 4 (OCT4) has been implicated in the development of hepatocellular carcinoma (HCC), although the findings are controversial. We conducted a meta-analysis to assess the correlation between OCT4 and the clinicopathological characteristics and the prognostic value in HCC. Methods: An electronic search for relevant articles was conducted in PubMed, Cochrane Library, Web of Science, EMBASE database, Chinese CNKI, and Chinese WanFang database. Correlations between OCT4 expression and clinicopathological features and survival outcomes were analyzed. Pooled odds ratios and hazard ratios with 95% CIs were calculated using STATA 14.2 software. Results: A total of 10 trials with 985 patients were included. Positive OCT4 expression was correlated with tumor size, tumor numbers, differentiation, and TNM stage. OCT4 expression was not correlated with gender, age, hepatitis B surface antigen, alfa-fetoprotein, liver cirrhosis, vascular invasion, or tumor encapsulation. OCT4 expression was associated with poor 3- and 5-year overall survival, and disease-free survival rate. Conclusion: OCT4 expression was associated with tumor size, tumor numbers, differentiation, and TNM stage in HCC. OCT4 may be a useful prognostic biomarker for HCC.
- 1 December 2017
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 47-57
Open AccessClinicopathological and prognostic significance of OCT4 in patients with hepatocellular carcinoma: a meta-analysis
Background and aims: Octamer-binding transcription factor 4 (OCT4) has been implicated in the development of hepatocellular carcinoma (HCC), although the findings are controversial. We conducted a meta-analysis to assess the correlation between OCT4 and the clinicopathological characteristics and the prognostic value in HCC. Methods: An electronic search for relevant articles was conducted in PubMed, Cochrane Library, Web of Science, EMBASE database, Chinese CNKI, and Chinese WanFang database. Correlations between OCT4 expression and clinicopathological features and survival outcomes were analyzed. Pooled odds ratios and hazard ratios with 95% CIs were calculated using STATA 14.2 software. Results: A total of 10 trials with 985 patients were included. Positive OCT4 expression was correlated with tumor size, tumor numbers, differentiation, and TNM stage. OCT4 expression was not correlated with gender, age, hepatitis B surface antigen, alfa-fetoprotein, liver cirrhosis, vascular invasion, or tumor encapsulation. OCT4 expression was associated with poor 3- and 5-year overall survival, and disease-free survival rate. Conclusion: OCT4 expression was associated with tumor size, tumor numbers, differentiation, and TNM stage in HCC. OCT4 may be a useful prognostic biomarker for HCC.
- Open Access
- 18 November 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (64) , 107543-107557
miR-564 inhibits hepatocellular carcinoma cell proliferation and invasion by targeting the GRB2-ERK1/2-AKT axis
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Chaojie Liang1, *, Yingchen Xu1, *, Hua Ge1, Bingchen Xing1, Guanqun Li1, Guangming Li1 and Jixiang Wu1 1Department of General Surgery, Beijing Tongren Hospital, Capital Medical University, Dongcheng, Beijing 100730, China *These authors are contributed equally to this work Correspondence to: Jixiang Wu, email: trwujixiang2016@126.com Guangming Li, email: liguangming2016@126.com Keywords: miR-564; HCC; GRB2; PI3K/AKT; ERK1/2 Received: August 21, 2017 Accepted: October 28, 2017 Published: November 18, 2017 ABSTRACT Recent studies have shown that miR-564 is closely related to the development of various tumors, including breast cancer, lung cancer and glioma. However, few studies have examined miR-564 in hepatocellular carcinoma (HCC). Here, we demonstrated that miR-564 expression in HCC tissues was lower than that in adjacent noncancerous tissues and that miR-564 expression was associated with tumor size, tumor number and vein invasion. Bioinformatics analyses showed that low levels of miR-564 were correlated with poor prognosis. Furthermore, upregulation of miR-564 impaired SMCC7721 and MHCC97H cell proliferation, migration and invasion in vitro and reduced tumorigenesis in vivo. Next, we found that GRB2 was a direct target gene of miR-564 in the HCC cell lines. GRB2 was highly expressed in HCC tissues and negatively correlated with miR-564 expression levels. When GRB2 was downregulated by GRB2-siRNA, HCC cell proliferation, invasion and metastasis were impaired, and restoring GRB2 expression partially reversed the inhibitory effects of miR-564. Western blot analysis showed that miR-564 overexpression reduced GRB2 expression in HCC cell lines and inhibited ERK1/2 and AKT phosphorylation. miR-564 overexpression also upregulated the epithelial-like cell marker E-cadherin and downregulated the interstitial cell-like markers N-cadherin and vimentin. These results suggest that miR-564 inhibits the malignant phenotype of HCC cells by targeting the GRB2-ERK1/2-AKT axis. Consequently, miR-564 may be used as a prognostic marker and therapeutic target for HCC.
- 18 November 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (64) , 107543-107557
Open AccessmiR-564 inhibits hepatocellular carcinoma cell proliferation and invasion by targeting the GRB2-ERK1/2-AKT axis
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Chaojie Liang1, *, Yingchen Xu1, *, Hua Ge1, Bingchen Xing1, Guanqun Li1, Guangming Li1 and Jixiang Wu1 1Department of General Surgery, Beijing Tongren Hospital, Capital Medical University, Dongcheng, Beijing 100730, China *These authors are contributed equally to this work Correspondence to: Jixiang Wu, email: trwujixiang2016@126.com Guangming Li, email: liguangming2016@126.com Keywords: miR-564; HCC; GRB2; PI3K/AKT; ERK1/2 Received: August 21, 2017 Accepted: October 28, 2017 Published: November 18, 2017 ABSTRACT Recent studies have shown that miR-564 is closely related to the development of various tumors, including breast cancer, lung cancer and glioma. However, few studies have examined miR-564 in hepatocellular carcinoma (HCC). Here, we demonstrated that miR-564 expression in HCC tissues was lower than that in adjacent noncancerous tissues and that miR-564 expression was associated with tumor size, tumor number and vein invasion. Bioinformatics analyses showed that low levels of miR-564 were correlated with poor prognosis. Furthermore, upregulation of miR-564 impaired SMCC7721 and MHCC97H cell proliferation, migration and invasion in vitro and reduced tumorigenesis in vivo. Next, we found that GRB2 was a direct target gene of miR-564 in the HCC cell lines. GRB2 was highly expressed in HCC tissues and negatively correlated with miR-564 expression levels. When GRB2 was downregulated by GRB2-siRNA, HCC cell proliferation, invasion and metastasis were impaired, and restoring GRB2 expression partially reversed the inhibitory effects of miR-564. Western blot analysis showed that miR-564 overexpression reduced GRB2 expression in HCC cell lines and inhibited ERK1/2 and AKT phosphorylation. miR-564 overexpression also upregulated the epithelial-like cell marker E-cadherin and downregulated the interstitial cell-like markers N-cadherin and vimentin. These results suggest that miR-564 inhibits the malignant phenotype of HCC cells by targeting the GRB2-ERK1/2-AKT axis. Consequently, miR-564 may be used as a prognostic marker and therapeutic target for HCC.